Mind Medicine (MindMed) Inc. Q4 FY2024 earnings call

2024 marked a year of progress for MindMed with key milestones in MM120 Phase 3 program, including positive Phase 2b results for GAD, pharmacokinetic bridging study, and new formulation patent. MM120 GAD program received Breakthrough Therapy designation. Pivotal Phase 3 studies for GAD (Voyage and Panorama) have dosed participants with early enrollment encouragement, and Phase 3 study for MDD (Emerge) to be dosed in H1 2025. Financially, ended 2024 with $273.7M in cash and cash equivalents, R&D expenses increased due to MM120 and MM402 programs, while G&A expenses decreased.

Cash and cash equivalents are expected to fund operations into 2027, with cash runway extending at least 12 months beyond first Phase 3 topline data for MM120 GAD. Topline readouts from Voyage GAD are expected in H1 2026, Panorama GAD in H2 2026, and Emerge MDD data in H2 2026. 2025 focus is on executing Phase 3 programs.

Forward-looking statements are subject to risks such as changes in market conditions, difficulties associated with research and development, and regulatory approval processes.

Q: Madhu Yennawar asked about GAD patient types likely to use MM120.

A: Rob and Dan discussed a broad swath of GAD patients, including severe, moderate, prior treated, and untreated patients.

Q: Gavin Clark-Gartner asked about enrollment updates and sample size re-estimation.

A: Rob mentioned no exact guidance yet, sample size re-estimation is no alpha spin, based on nuisance parameters like dropout rate and pooled variance.

Q: Nevin asked about enrollment tracking and psychedelic awareness.

A: Rob and Dan discussed similar inclusion/exclusion criteria to Phase 2, broad patient population, and expectancy in trials.

Q: Charles Duncan asked about enrollment criteria and Panorama dose.

A: Dan discussed representative patient sample, inclusion/exclusion similar to Phase 2, and dose response in Phase 2 showing stark difference between 50 and 100 micrograms.

Q: Francois Brisebois asked about PTSD AdCom.

A: Rob said they watch AdComs but focus on their own development and don't see direct impact on their program.

Q: Joel Beatty asked about patients taking other therapies.

A: Rob discussed protocol adherence and statistical plan handling for patients taking other therapies during the trial.

Q: Rudy Li asked about MDD indication and interactions with FDA.

A: Rob discussed broad market opportunity and positive interactions with FDA, including breakthrough therapy designation.

Q: Sumant Kulkarni asked about FDA interactions and competition.

A: Rob discussed FDA engagement and site economics, noting MM120's magnitude and durability compared to competitors.

Q: Patrick Trucchio asked about long-term durability and HEOR.

A: Rob discussed durability measurement in Part B of studies and HEOR research on prevalence, quality of life, and economic burden of GAD.

Q: Michael Okunewitch asked about MDD confirmatory study.

A: Rob discussed considering MDD program in financial projections and ongoing planning for the MDD study